Nonpathogenic recombinant monoclonal anti-AQP4 Ab, called “aquaporumab,” was recently shown to dramatically reduce NMO-like lesions in an ex vivo spinal cord slice model [46]. This evidence concerns the gene AQP4 and neuromyelitis optica.